BETTER THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.01 USD | +11.11% |
|
+61.29% | -94.87% |
| Mar. 21 | Better Therapeutics, Inc. Receives Notice of Default from Hercules Capital, Inc | CI |
| Mar. 20 | Better Therapeutics, Inc.(NasdaqCM:BTTX) dropped from S&P TMI Index | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Capitalization 1 | 109.7 | 26.24 | 0.5452 | 0.5452 |
| Enterprise Value (EV) 1 | 78.68 | 26.24 | 0.5452 | 0.5452 |
| P/E ratio | -1.5 x | -0.65 x | -0.01 x | -0.01 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | - | - | 0.14 x |
| EV / Revenue | - | - | - | 0.14 x |
| EV / EBITDA | - | - | - | - |
| EV / FCF | -3,554,519 x | -903,616 x | - | - |
| FCF Yield | -0% | -0% | - | - |
| Price to Book | - | - | - | - |
| Nbr of stocks (in thousands) | 23,600 | 23,744 | 54,516 | 54,516 |
| Reference price 2 | 4.650 | 1.105 | 0.0100 | 0.0100 |
| Announcement Date | 3/28/22 | 3/30/23 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | 3.8 |
| EBITDA | - | - | - | - | - |
| EBIT 1 | - | -30.56 | -38.26 | -27.1 | -47.6 |
| Operating Margin | - | - | - | - | -1,252.63% |
| Earnings before Tax (EBT) 1 | - | -40.49 | -39.75 | -28.7 | -47.7 |
| Net income 1 | -6.387 | -40.34 | -39.76 | -28.7 | -47.7 |
| Net margin | - | - | - | - | -1,255.26% |
| EPS 2 | -2.050 | -3.110 | -1.690 | -0.8100 | -1.000 |
| Free Cash Flow | - | -30.87 | -29.04 | - | - |
| FCF margin | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 4/23/21 | 3/28/22 | 3/30/23 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -0.2404 | -12.1 | -9.345 | -9.599 | -11 | -8.322 | -8.925 | -7.025 | -5.341 | -5.8 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -0.2389 | -13.9 | -9.662 | -9.928 | -11.4 | -8.761 | -9.356 | -7.588 | -5.859 | -5.9 |
| Net income 1 | -0.2389 | -13.89 | -9.662 | -9.928 | -11.4 | -8.765 | -9.357 | -7.589 | -5.862 | -5.9 |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.0300 | -0.7100 | -0.4100 | -0.4200 | -0.4800 | -0.3700 | -0.3900 | -0.2400 | -0.1500 | -0.1200 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/23/21 | 3/28/22 | 5/13/22 | 8/11/22 | 11/14/22 | 3/30/23 | 5/11/23 | 8/9/23 | 11/9/23 | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | 31.1 | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow | - | -30.9 | -29 | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex | - | 0.06 | - | - | - |
| Capex / Sales | - | - | - | - | - |
| Announcement Date | 4/23/21 | 3/28/22 | 3/30/23 | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.01
USD
Average target price
1.5
USD
Spread / Average Target
+14,900.00%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -94.87% | 545K | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- BTTX Stock
- Financials Better Therapeutics, Inc.
